Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy

To evaluate the efficacy and safety of capecitabine and cisplatin in patients with recurrent gastric cancer after fluoropyrimidine-based adjuvant therapy. Patients with histologically confirmed and measurable advanced gastric cancer that had relapsed after fluoropyrimidine-based adjuvant chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, H J, Chang, H M, Kim, T W, Ryu, M-H, Sohn, H J, Yook, J H, Oh, S T, Kim, B S, Lee, J-S, Kang, Y-K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361863/
https://www.ncbi.nlm.nih.gov/pubmed/15655540
http://dx.doi.org/10.1038/sj.bjc.6602336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361863/
https://www.ncbi.nlm.nih.gov/pubmed/15655540
http://dx.doi.org/10.1038/sj.bjc.6602336

Ejemplares similares